ESMO

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage
Endpoints
ESMO
Eli Lilly
Pfizer
Novartis
abemaciclib
breast cancer
Flag link:
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals
Fierce Pharma
ESMO
Merck
Keytruda
bladder cancer
Flag link:
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
Fierce Pharma
ESMO
AstraZeneca
Imfinzi
lung cancer
Flag link:
ESMO17: Clovis seeking new indication on positive ARIEL3 data
ESMO17: Clovis seeking new indication on positive ARIEL3 data
BioPharma Dive
ESMO
Clovis Oncology
Rubraca
ovarian cancer
Flag link:
ESMO: AstraZeneca's Tagrisso bests rivals at holding off EGFR lung cancer growth
ESMO: AstraZeneca's Tagrisso bests rivals at holding off EGFR lung cancer growth
Fierce Pharma
AstraZeneca
ESMO
Tagrisso
Flag link:
ESMO: Merck piles on the positive Keytruda-chemo combo results in lung cancer
ESMO: Merck piles on the positive Keytruda-chemo combo results in lung cancer
Fierce Pharma
Merck
Keytruda
ESMO
lung cancer
Flag link:
ESMO: The latest skinny on drugs from Pfizer, Novartis, GSK, Merck, BMS
ESMO: The latest skinny on drugs from Pfizer, Novartis, GSK, Merck, BMS
Fierce Pharma
ESMO
Pfizer
Novartis
GSK
Merck
Bristol-Myers Squibb
Flag link:
3 Clear Winners of ESMO 2010
3 Clear Winners of ESMO 2010
Seeking Alpha
ESMO
cancer
Aveo Pharmaceutical
Arqule
Dendreon
Immunogen
Roche
Medarex
Seattle Genetics
Sanofi
Flag link: